chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Rash pruritic, Vaccination site erythema, Vaccination site swelling
Clinical narrative: Swelling at injection site.; Redness at injection site.; Itchy rash at injection site; This is a spontaneous report from a contactable consumer, the patient. A 68-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6199) via an unspecified route of administration in right arm on 08March2021 at 09:45 (at the age of 68-year-old), as a single dose for COVID-19 immunisation. Medical history included mild chronic obstructive pulmonary disease, high cholesterol and blood pressure. The patient was allergic to several pain medications, antibiotics and bee stings. The patient received unspecified medications within 2 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested positive for COVID-19. The patient did not receive any other vaccine within four weeks prior to COVID-19 vaccine. On 18March2021 at 12:30, after 10 days of vaccination the patient experienced injection site swelling, injection site redness and itchy rash at injection site. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events vaccination site swelling, vaccination site erythema and itchy rash. The clinical outcome of vaccination site swelling, vaccination site erythema and itchy rash was recovering at the time of this report.   No follow up attempts are needed. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Ear discomfort, Hypoacusis, Tinnitus
Clinical narrative: Very loud ringing in ears which interfered with hearing; ears felt weird; This is a spontaneous report received from a contactable consumer, the patient. A 58-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6205) via an unspecified route of administration in left arm on 01Mar2021 at 16:45 (age at vaccination 58-years) as a single dose for COVID-19 immunisation. Past medical histories included premature ventricular contractions (PVCs) and mitral valve prolapse. The patient was allergic to Sulfa, Emycin and Zantac. Concomitant medications included Prozac, fish oil (MANUFACTURER UNKNOWN) and turmeric (MANUFACTURER UNKNOWN). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 04Mar2021, the patient experienced very loud ringing in her ears which interfered with hearing and ears felt weird. The events resulted in doctor or other healthcare professional office/clinic visit. The patient received treatment with Flonase and antihistamine (unspecified). The clinical outcome of the events loud ringing in ears and ears felt weird were recovering at the time of reporting.   No follow-up attempts are needed. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Ear discomfort, Tinnitus
Clinical narrative: Very loud ringing in ears which interfered with hearing; ears felt weird; This is a spontaneous report received from a contactable consumer, the patient. A 58-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6205) via an unspecified route of administration in left arm on 01Mar2021 at 16:45 (age at vaccination 58-years) as a single dose for COVID-19 immunisation. Past medical histories included premature ventricular contractions (PVCs) and mitral valve prolapse. The patient was allergic to Sulfa, Emycin and Zantac. Concomitant medications included Prozac, fish oil (MANUFACTURER UNKNOWN) and turmeric (MANUFACTURER UNKNOWN). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 04Mar2021, the patient experienced very loud ringing in her ears which interfered with hearing and ears felt weird. The events resulted in doctor or other healthcare professional office/clinic visit. The patient received treatment with Flonase and antihistamine (unspecified). The clinical outcome of the events loud ringing in ears and ears felt weird were recovering at the time of reporting.   No follow-up attempts are needed. No further information is expected.
Age: 24.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Cheilitis, Feeling abnormal, Hypersensitivity, Paraesthesia oral
Clinical narrative: Bumps on lips; Mouth, tongue and lips tingling; Dry mouth, tongue and lips; Sensitive mouth, tongue and lips; This is a spontaneous report received from a contactable consumer, the patient. A 24-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number EP6955), via an unspecified route of administration in the left arm on 19Mar2021 at 09:15 (at an age of 24-years-old), as a single dose for COVID-19 immunisation. Medical history included severe nut allergy (cashews, walnuts, pistachio and sesame seeds). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications include VYNASE, SUDAFED, ADDRELL and ADVIL; all for unspecified indication from unknown date. On 19Mar2021 at 09:30, the patient experienced minor allergic reaction similar to those experienced when she had a reaction to nuts. The patient also had bumps on lips; mouth, tongue and lips were tingling, dry and sensitive. The patient did not receive any treatment for the reported events. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. The clinical outcome of bumps on lips; mouth, tongue and lips were tingling, dry and sensitive was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 24.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dry mouth, Lip disorder, Oral pain, Paraesthesia oral
Clinical narrative: Bumps on lips; Mouth, tongue and lips tingling; Dry mouth, tongue and lips; Sensitive mouth, tongue and lips; This is a spontaneous report received from a contactable consumer, the patient. A 24-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number EP6955), via an unspecified route of administration in the left arm on 19Mar2021 at 09:15 (at an age of 24-years-old), as a single dose for COVID-19 immunisation. Medical history included severe nut allergy (cashews, walnuts, pistachio and sesame seeds). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications include VYNASE, SUDAFED, ADDRELL and ADVIL; all for unspecified indication from unknown date. On 19Mar2021 at 09:30, the patient experienced minor allergic reaction similar to those experienced when she had a reaction to nuts. The patient also had bumps on lips; mouth, tongue and lips were tingling, dry and sensitive. The patient did not receive any treatment for the reported events. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. The clinical outcome of bumps on lips; mouth, tongue and lips were tingling, dry and sensitive was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Chills, Diarrhoea, Pain, Pyrexia, Vomiting
Clinical narrative: Vomiting; Diarrhea; High fever; Body ache; Chills; This is a spontaneous report received from a contactable consumer, the patient. A 49-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EM6204) via an unspecified route of administration in the left arm on 18Mar2021 at 15:30 as a single dose (at the age of 49-year-old) for COVID-19 immunisation. The patient had no allergies to medications, food, or other products. The patient medical history included hypothyroidism. Concomitant medication included levothyroxine (MANUFACTURER UNKNOWN), biotin (MANUFACTURER UNKNOWN, fish oil (MANUFACTURER UNKNOWN, vitamin D (MANUFACTURER UNKNOWN and turmeric (MANUFACTURER UNKNOWN). Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 19Mar2021 at 17:00, the patient had experienced vomiting, diarrhea, high fever, body aches, and chills. The patient did not receive treatment for the event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events vomiting, diarrhea, high fever, body aches and chills was recovered.   No follow-up attempts are possible. No further information is expected.
Age: 63.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Tinnitus
Clinical narrative: Left ear tinnitus; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: unknown) via an unspecified route of administration on an unknown date (at the age of 63-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not receive any medication within 2 weeks of vaccination. The patient had no known allergies to medications, food, or other products. The patient did not receive any other vaccines in four weeks prior to COVID-19 vaccination. Prior to vaccination the patient was not diagnosed with COVID-19. The patient had not been tested for COVID-19 since the vaccination. On 17Mar2021 at 16:30, the patient experienced left ear tinnitus. No therapeutic measures were taken for the event. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of tinnitus was not resolved at the time of this report.   Information about lot/batch number cannot be obtained. No further information is expected.
Age: 53.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Burning sensation, Chills, Feeling cold, Mobility decreased, Neck pain
Clinical narrative: Freezing chills; Temperature of 101; This is a spontaneous report received from a contactable consumer, the patient. A 53-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER2613) via an unspecified route of administration in the left arm on 20Mar2021 at 10:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient had no any allergies to medications, food or other products. The patient did not receive any concomitant medications within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 20Mar2021 at 23:30, the patient experienced temperature of 101 (units unspecified) and freezing chills. Therapeutic measures included Tylenol pm to keep fever down, however did not know if it would have gone higher. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events temperature of 101 (units unspecified) and freezing chills was not resolved at the time of reporting. No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Pain in extremity, Pyrexia, Tremor
Clinical narrative: Freezing chills; Temperature of 101; This is a spontaneous report received from a contactable consumer, the patient. A 53-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER2613) via an unspecified route of administration in the left arm on 20Mar2021 at 10:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient had no any allergies to medications, food or other products. The patient did not receive any concomitant medications within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 20Mar2021 at 23:30, the patient experienced temperature of 101 (units unspecified) and freezing chills. Therapeutic measures included Tylenol pm to keep fever down, however did not know if it would have gone higher. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events temperature of 101 (units unspecified) and freezing chills was not resolved at the time of reporting. No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Body temperature, Chills, Pyrexia
Clinical narrative: Freezing chills; Temperature of 101; This is a spontaneous report received from a contactable consumer, the patient. A 53-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER2613) via an unspecified route of administration in the left arm on 20Mar2021 at 10:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient had no any allergies to medications, food or other products. The patient did not receive any concomitant medications within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 20Mar2021 at 23:30, the patient experienced temperature of 101 (units unspecified) and freezing chills. Therapeutic measures included Tylenol pm to keep fever down, however did not know if it would have gone higher. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events temperature of 101 (units unspecified) and freezing chills was not resolved at the time of reporting. No follow-up attempts are needed. No further information is expected.
Age: 71.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Lip swelling, Swollen tongue
Clinical narrative: Numbness lips, tongue, palate; Vaccine administered at inappropriate site; This is a spontaneous report received from a contactable consumer, the patient. A 71-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER2613), via an unspecified route of administration on 20Mar2021, at 11:15 (at the age of 71-years-old) on gluteus medius right (right buttock), as a single dose for COVID-19 immunisation. Medical history included gluten intolerance and lactose intolerance. Concomitant medications included unspecified decongestant and acetylsalicylic acid; caffeine; paracetamol (EXCEDRIN), for unknown indications from unknown dates. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 20Mar2021 at 11:15, the patient experienced numbness in lips, tongue and palate. The patient had vaccine administered at inappropriate site. The adverse event did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event numbness lips, tongue, palate was not recovered at the time of the report while that of vaccine administered at inappropriate site was unknown.   No follow-up attempts are needed. No further information is expected.
Age: 71.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Hypoaesthesia oral, Lip swelling, Swelling face, Swollen tongue
Clinical narrative: Numbness lips, tongue, palate; Vaccine administered at inappropriate site; This is a spontaneous report received from a contactable consumer, the patient. A 71-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER2613), via an unspecified route of administration on 20Mar2021, at 11:15 (at the age of 71-years-old) on gluteus medius right (right buttock), as a single dose for COVID-19 immunisation. Medical history included gluten intolerance and lactose intolerance. Concomitant medications included unspecified decongestant and acetylsalicylic acid; caffeine; paracetamol (EXCEDRIN), for unknown indications from unknown dates. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 20Mar2021 at 11:15, the patient experienced numbness in lips, tongue and palate. The patient had vaccine administered at inappropriate site. The adverse event did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event numbness lips, tongue, palate was not recovered at the time of the report while that of vaccine administered at inappropriate site was unknown.   No follow-up attempts are needed. No further information is expected.
Age: 71.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Hypoaesthesia oral, Product administered at inappropriate site
Clinical narrative: Numbness lips, tongue, palate; Vaccine administered at inappropriate site; This is a spontaneous report received from a contactable consumer, the patient. A 71-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER2613), via an unspecified route of administration on 20Mar2021, at 11:15 (at the age of 71-years-old) on gluteus medius right (right buttock), as a single dose for COVID-19 immunisation. Medical history included gluten intolerance and lactose intolerance. Concomitant medications included unspecified decongestant and acetylsalicylic acid; caffeine; paracetamol (EXCEDRIN), for unknown indications from unknown dates. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 20Mar2021 at 11:15, the patient experienced numbness in lips, tongue and palate. The patient had vaccine administered at inappropriate site. The adverse event did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event numbness lips, tongue, palate was not recovered at the time of the report while that of vaccine administered at inappropriate site was unknown.   No follow-up attempts are needed. No further information is expected.
Age: 58.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Asthenia, Diarrhoea, Headache, Pain
Clinical narrative: Body aches; Fever; Diarrhea; Joint pain; Headache; Sore arm; This is a spontaneous report from a contactable consumer, the patient. A 58-years-old adult male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA vaccine; Lot number: ER8727), via an unspecified route of administration in the left arm on 20Mar2021, at 10:30 (at the age of 58-years-old), as a single dose for COVID-19 immunisation. Medical history included type 2 diabetes, high blood pressure and high cholesterol. The patient had no allergies to food or medications. Concomitant medications included diltiazem (MANUFACTURER UNKNOWN), atorvastatin (MANUFACTURER UNKNOWN), lisinopril (MANUFACTURER UNKNOWN) and fluvoxamine (MANUFACTURER UNKNOWN), all from an unknown date and for unknown indication. Prior to vaccination, the patient had no symptoms associated for COVID-19. Since the vaccination, the patient was not tested positive for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the vaccine. On 19Mar2021 at 13:00, the patient experienced fever, body aches, diarrhea, joint pain, headache and sore arm. No therapeutic measures were taken as a result of events. The clinical outcome of events fever, body aches, diarrhea, joint pain, headache and sore arm were resolving at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 58.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Pain in extremity, Pyrexia
Clinical narrative: Body aches; Fever; Diarrhea; Joint pain; Headache; Sore arm; This is a spontaneous report from a contactable consumer, the patient. A 58-years-old adult male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA vaccine; Lot number: ER8727), via an unspecified route of administration in the left arm on 20Mar2021, at 10:30 (at the age of 58-years-old), as a single dose for COVID-19 immunisation. Medical history included type 2 diabetes, high blood pressure and high cholesterol. The patient had no allergies to food or medications. Concomitant medications included diltiazem (MANUFACTURER UNKNOWN), atorvastatin (MANUFACTURER UNKNOWN), lisinopril (MANUFACTURER UNKNOWN) and fluvoxamine (MANUFACTURER UNKNOWN), all from an unknown date and for unknown indication. Prior to vaccination, the patient had no symptoms associated for COVID-19. Since the vaccination, the patient was not tested positive for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the vaccine. On 19Mar2021 at 13:00, the patient experienced fever, body aches, diarrhea, joint pain, headache and sore arm. No therapeutic measures were taken as a result of events. The clinical outcome of events fever, body aches, diarrhea, joint pain, headache and sore arm were resolving at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 58.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Diarrhoea, Headache, Pain, Pain in extremity
Clinical narrative: Body aches; Fever; Diarrhea; Joint pain; Headache; Sore arm; This is a spontaneous report from a contactable consumer, the patient. A 58-years-old adult male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA vaccine; Lot number: ER8727), via an unspecified route of administration in the left arm on 20Mar2021, at 10:30 (at the age of 58-years-old), as a single dose for COVID-19 immunisation. Medical history included type 2 diabetes, high blood pressure and high cholesterol. The patient had no allergies to food or medications. Concomitant medications included diltiazem (MANUFACTURER UNKNOWN), atorvastatin (MANUFACTURER UNKNOWN), lisinopril (MANUFACTURER UNKNOWN) and fluvoxamine (MANUFACTURER UNKNOWN), all from an unknown date and for unknown indication. Prior to vaccination, the patient had no symptoms associated for COVID-19. Since the vaccination, the patient was not tested positive for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the vaccine. On 19Mar2021 at 13:00, the patient experienced fever, body aches, diarrhea, joint pain, headache and sore arm. No therapeutic measures were taken as a result of events. The clinical outcome of events fever, body aches, diarrhea, joint pain, headache and sore arm were resolving at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 58.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Pyrexia
Clinical narrative: Body aches; Fever; Diarrhea; Joint pain; Headache; Sore arm; This is a spontaneous report from a contactable consumer, the patient. A 58-years-old adult male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA vaccine; Lot number: ER8727), via an unspecified route of administration in the left arm on 20Mar2021, at 10:30 (at the age of 58-years-old), as a single dose for COVID-19 immunisation. Medical history included type 2 diabetes, high blood pressure and high cholesterol. The patient had no allergies to food or medications. Concomitant medications included diltiazem (MANUFACTURER UNKNOWN), atorvastatin (MANUFACTURER UNKNOWN), lisinopril (MANUFACTURER UNKNOWN) and fluvoxamine (MANUFACTURER UNKNOWN), all from an unknown date and for unknown indication. Prior to vaccination, the patient had no symptoms associated for COVID-19. Since the vaccination, the patient was not tested positive for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the vaccine. On 19Mar2021 at 13:00, the patient experienced fever, body aches, diarrhea, joint pain, headache and sore arm. No therapeutic measures were taken as a result of events. The clinical outcome of events fever, body aches, diarrhea, joint pain, headache and sore arm were resolving at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 60.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Pain of skin
Clinical narrative: Elbow and ankle joint pain; Skin tenderness; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN 6205) via an unspecified route of administration in the left arm on 07Mar2021 at 12:00 (at an age of 60-year-old) as a single dose for COVID-19 immunisation. The patients medical history included acid reflux, Chronic obstructive pulmonary disease (COPD), Kaposis sarcoma and unspecified allergies. The patient was allergic to nonsteroidal anti-inflammatory drug (NSAID). Concomitant medication included omeprazole (MANUFACTURER UNKNOWN) for an unknown indication. Prior to vaccination, patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Since the vaccination, has the patient was not tested for COVID-19. On 09Mar2021 at 09:00, the patient experienced elbow and ankle joint pain and skin tenderness. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events elbow and ankle joint pain, skin tenderness was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 27.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Asthenia, Dizziness, Fatigue, Headache, Injection site pruritus
Clinical narrative: Dizziness; Runny nose; Weakness; Exhaustion/ Fatigue; Injection site itchiness; Face and arm itchiness; Headache; This is spontaneous report from a contactable consumer, the patient. A 27-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534) via an unspecified route of administration in the right arm on 18Mar2021 at 15:45 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma, allergies (unspecified) and obesity. It was provided that the patient was not allergic to medications, food, or other products. Concomitant medications included Zyrtec, trazodone (MANUFACTURER UNKNOWN), D3 (MANUFACTURER UNKNOWN), B12 (MANUFACTURER UNKNOWN), vitamin C (MANUFACTURER UNKNOWN) and fish oil (MANUFACTURER UNKNOWN). Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccination. Since the vaccination, the patient was not tested for COVID-19. On 18Mar2021 at 18:00, the patient experienced exhaustion, fatigue, dizziness, weakness, injection site itchiness, face and arm itchiness, runny nose and headache. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic treatment was taken for the reported events. The clinical outcome of the events exhaustion, dizziness, weakness, injection site itchiness, face and arm itchiness, runny nose and headache were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 27.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pruritus, Rhinorrhoea
Clinical narrative: Dizziness; Runny nose; Weakness; Exhaustion/ Fatigue; Injection site itchiness; Face and arm itchiness; Headache; This is spontaneous report from a contactable consumer, the patient. A 27-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534) via an unspecified route of administration in the right arm on 18Mar2021 at 15:45 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma, allergies (unspecified) and obesity. It was provided that the patient was not allergic to medications, food, or other products. Concomitant medications included Zyrtec, trazodone (MANUFACTURER UNKNOWN), D3 (MANUFACTURER UNKNOWN), B12 (MANUFACTURER UNKNOWN), vitamin C (MANUFACTURER UNKNOWN) and fish oil (MANUFACTURER UNKNOWN). Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccination. Since the vaccination, the patient was not tested for COVID-19. On 18Mar2021 at 18:00, the patient experienced exhaustion, fatigue, dizziness, weakness, injection site itchiness, face and arm itchiness, runny nose and headache. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic treatment was taken for the reported events. The clinical outcome of the events exhaustion, dizziness, weakness, injection site itchiness, face and arm itchiness, runny nose and headache were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 27.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Asthenia, Dizziness, Fatigue, Headache, Pruritus
Clinical narrative: Dizziness; Runny nose; Weakness; Exhaustion/ Fatigue; Injection site itchiness; Face and arm itchiness; Headache; This is spontaneous report from a contactable consumer, the patient. A 27-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534) via an unspecified route of administration in the right arm on 18Mar2021 at 15:45 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma, allergies (unspecified) and obesity. It was provided that the patient was not allergic to medications, food, or other products. Concomitant medications included Zyrtec, trazodone (MANUFACTURER UNKNOWN), D3 (MANUFACTURER UNKNOWN), B12 (MANUFACTURER UNKNOWN), vitamin C (MANUFACTURER UNKNOWN) and fish oil (MANUFACTURER UNKNOWN). Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccination. Since the vaccination, the patient was not tested for COVID-19. On 18Mar2021 at 18:00, the patient experienced exhaustion, fatigue, dizziness, weakness, injection site itchiness, face and arm itchiness, runny nose and headache. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic treatment was taken for the reported events. The clinical outcome of the events exhaustion, dizziness, weakness, injection site itchiness, face and arm itchiness, runny nose and headache were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 27.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Rhinorrhoea, Vaccination site pruritus
Clinical narrative: Dizziness; Runny nose; Weakness; Exhaustion/ Fatigue; Injection site itchiness; Face and arm itchiness; Headache; This is spontaneous report from a contactable consumer, the patient. A 27-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534) via an unspecified route of administration in the right arm on 18Mar2021 at 15:45 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma, allergies (unspecified) and obesity. It was provided that the patient was not allergic to medications, food, or other products. Concomitant medications included Zyrtec, trazodone (MANUFACTURER UNKNOWN), D3 (MANUFACTURER UNKNOWN), B12 (MANUFACTURER UNKNOWN), vitamin C (MANUFACTURER UNKNOWN) and fish oil (MANUFACTURER UNKNOWN). Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccination. Since the vaccination, the patient was not tested for COVID-19. On 18Mar2021 at 18:00, the patient experienced exhaustion, fatigue, dizziness, weakness, injection site itchiness, face and arm itchiness, runny nose and headache. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic treatment was taken for the reported events. The clinical outcome of the events exhaustion, dizziness, weakness, injection site itchiness, face and arm itchiness, runny nose and headache were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Chills, Fatigue, Headache, Injection site erythema
Clinical narrative: Severe chills; fever of 101; Nausea; Vomiting; Headache; extreme thirst; body aches; joint aches; injection site swelling; injection site pain; injection site redness; loss of appetite; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6204), via an unspecified route of administration in the right arm on 18Mar2021 at 09:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. Medical history included metastatic papillary carcinoma since an unknown date in 1986 and 1993 and thyroidectomy on an unknown date of 1986 resulting in hypothyroidism and hyperparathyroidism. The patient was allergic to compazine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6200) via an unspecified route of administration in the right arm on 25Feb2021 at 09:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines in four weeks prior to COVID-19 vaccination. Prior to vaccination the patient was not diagnosed with COVID-19. The patient had not been tested for COVID-19 since the vaccination. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN), calcitriol (MANUFACTURER UNKNOWN) and calcium citrate (MANUFACTURER UNKNOWN) from an unknown date for unknown indication. On 18Mar2021 at 19:00, the patient had severe chills, fever of 101(units unspecified), nausea, vomiting, headaches, extreme thirst, body aches, joint aches, injection site swelling, injection site redness, injection site pain and loss of appetite. On an unknown date, the patient had lab test included fever of 101 (units unspecified). The patient did not receive any treatment for the events. The Clinical outcome of severe chills, fever of 101(units unspecified), nausea, vomiting, headaches, extreme thirst, body aches, joint aches, injection site swelling, injection site redness, injection site pain and loss of appetite was resolving at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Injection site pain, Injection site swelling, Nausea, Pain, Pyrexia
Clinical narrative: Severe chills; fever of 101; Nausea; Vomiting; Headache; extreme thirst; body aches; joint aches; injection site swelling; injection site pain; injection site redness; loss of appetite; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6204), via an unspecified route of administration in the right arm on 18Mar2021 at 09:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. Medical history included metastatic papillary carcinoma since an unknown date in 1986 and 1993 and thyroidectomy on an unknown date of 1986 resulting in hypothyroidism and hyperparathyroidism. The patient was allergic to compazine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6200) via an unspecified route of administration in the right arm on 25Feb2021 at 09:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines in four weeks prior to COVID-19 vaccination. Prior to vaccination the patient was not diagnosed with COVID-19. The patient had not been tested for COVID-19 since the vaccination. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN), calcitriol (MANUFACTURER UNKNOWN) and calcium citrate (MANUFACTURER UNKNOWN) from an unknown date for unknown indication. On 18Mar2021 at 19:00, the patient had severe chills, fever of 101(units unspecified), nausea, vomiting, headaches, extreme thirst, body aches, joint aches, injection site swelling, injection site redness, injection site pain and loss of appetite. On an unknown date, the patient had lab test included fever of 101 (units unspecified). The patient did not receive any treatment for the events. The Clinical outcome of severe chills, fever of 101(units unspecified), nausea, vomiting, headaches, extreme thirst, body aches, joint aches, injection site swelling, injection site redness, injection site pain and loss of appetite was resolving at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Thirst, Vomiting
Clinical narrative: Severe chills; fever of 101; Nausea; Vomiting; Headache; extreme thirst; body aches; joint aches; injection site swelling; injection site pain; injection site redness; loss of appetite; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6204), via an unspecified route of administration in the right arm on 18Mar2021 at 09:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. Medical history included metastatic papillary carcinoma since an unknown date in 1986 and 1993 and thyroidectomy on an unknown date of 1986 resulting in hypothyroidism and hyperparathyroidism. The patient was allergic to compazine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6200) via an unspecified route of administration in the right arm on 25Feb2021 at 09:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines in four weeks prior to COVID-19 vaccination. Prior to vaccination the patient was not diagnosed with COVID-19. The patient had not been tested for COVID-19 since the vaccination. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN), calcitriol (MANUFACTURER UNKNOWN) and calcium citrate (MANUFACTURER UNKNOWN) from an unknown date for unknown indication. On 18Mar2021 at 19:00, the patient had severe chills, fever of 101(units unspecified), nausea, vomiting, headaches, extreme thirst, body aches, joint aches, injection site swelling, injection site redness, injection site pain and loss of appetite. On an unknown date, the patient had lab test included fever of 101 (units unspecified). The patient did not receive any treatment for the events. The Clinical outcome of severe chills, fever of 101(units unspecified), nausea, vomiting, headaches, extreme thirst, body aches, joint aches, injection site swelling, injection site redness, injection site pain and loss of appetite was resolving at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Chills, Decreased appetite, Headache, Nausea
Clinical narrative: Severe chills; fever of 101; Nausea; Vomiting; Headache; extreme thirst; body aches; joint aches; injection site swelling; injection site pain; injection site redness; loss of appetite; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6204), via an unspecified route of administration in the right arm on 18Mar2021 at 09:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. Medical history included metastatic papillary carcinoma since an unknown date in 1986 and 1993 and thyroidectomy on an unknown date of 1986 resulting in hypothyroidism and hyperparathyroidism. The patient was allergic to compazine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6200) via an unspecified route of administration in the right arm on 25Feb2021 at 09:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines in four weeks prior to COVID-19 vaccination. Prior to vaccination the patient was not diagnosed with COVID-19. The patient had not been tested for COVID-19 since the vaccination. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN), calcitriol (MANUFACTURER UNKNOWN) and calcium citrate (MANUFACTURER UNKNOWN) from an unknown date for unknown indication. On 18Mar2021 at 19:00, the patient had severe chills, fever of 101(units unspecified), nausea, vomiting, headaches, extreme thirst, body aches, joint aches, injection site swelling, injection site redness, injection site pain and loss of appetite. On an unknown date, the patient had lab test included fever of 101 (units unspecified). The patient did not receive any treatment for the events. The Clinical outcome of severe chills, fever of 101(units unspecified), nausea, vomiting, headaches, extreme thirst, body aches, joint aches, injection site swelling, injection site redness, injection site pain and loss of appetite was resolving at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pain, Pyrexia, Thirst, Vaccination site erythema, Vaccination site pain
Clinical narrative: Severe chills; fever of 101; Nausea; Vomiting; Headache; extreme thirst; body aches; joint aches; injection site swelling; injection site pain; injection site redness; loss of appetite; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6204), via an unspecified route of administration in the right arm on 18Mar2021 at 09:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. Medical history included metastatic papillary carcinoma since an unknown date in 1986 and 1993 and thyroidectomy on an unknown date of 1986 resulting in hypothyroidism and hyperparathyroidism. The patient was allergic to compazine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6200) via an unspecified route of administration in the right arm on 25Feb2021 at 09:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines in four weeks prior to COVID-19 vaccination. Prior to vaccination the patient was not diagnosed with COVID-19. The patient had not been tested for COVID-19 since the vaccination. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN), calcitriol (MANUFACTURER UNKNOWN) and calcium citrate (MANUFACTURER UNKNOWN) from an unknown date for unknown indication. On 18Mar2021 at 19:00, the patient had severe chills, fever of 101(units unspecified), nausea, vomiting, headaches, extreme thirst, body aches, joint aches, injection site swelling, injection site redness, injection site pain and loss of appetite. On an unknown date, the patient had lab test included fever of 101 (units unspecified). The patient did not receive any treatment for the events. The Clinical outcome of severe chills, fever of 101(units unspecified), nausea, vomiting, headaches, extreme thirst, body aches, joint aches, injection site swelling, injection site redness, injection site pain and loss of appetite was resolving at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Vaccination site swelling, Vomiting
Clinical narrative: Severe chills; fever of 101; Nausea; Vomiting; Headache; extreme thirst; body aches; joint aches; injection site swelling; injection site pain; injection site redness; loss of appetite; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6204), via an unspecified route of administration in the right arm on 18Mar2021 at 09:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. Medical history included metastatic papillary carcinoma since an unknown date in 1986 and 1993 and thyroidectomy on an unknown date of 1986 resulting in hypothyroidism and hyperparathyroidism. The patient was allergic to compazine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6200) via an unspecified route of administration in the right arm on 25Feb2021 at 09:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines in four weeks prior to COVID-19 vaccination. Prior to vaccination the patient was not diagnosed with COVID-19. The patient had not been tested for COVID-19 since the vaccination. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN), calcitriol (MANUFACTURER UNKNOWN) and calcium citrate (MANUFACTURER UNKNOWN) from an unknown date for unknown indication. On 18Mar2021 at 19:00, the patient had severe chills, fever of 101(units unspecified), nausea, vomiting, headaches, extreme thirst, body aches, joint aches, injection site swelling, injection site redness, injection site pain and loss of appetite. On an unknown date, the patient had lab test included fever of 101 (units unspecified). The patient did not receive any treatment for the events. The Clinical outcome of severe chills, fever of 101(units unspecified), nausea, vomiting, headaches, extreme thirst, body aches, joint aches, injection site swelling, injection site redness, injection site pain and loss of appetite was resolving at the time of this report. No follow-up attempts are needed. No further information is expected.